Machine-Learning Driven Drug Repurposing for COVID-19

• URL: http://arxiv.org/abs/2006.14707v1
• Date: Thu, 25 Jun 2020 21:18:53 GMT
• Title: Machine-Learning Driven Drug Repurposing for COVID-19
• Authors: Semih Cant\"urk, Aman Singh, Patrick St-Amant, Jason Behrmann
• Abstract summary: We aim to discover the underlying associations between viral proteins and antiviral therapeutics by employing neural network models. We trained ANN models with virus protein sequences as inputs and antiviral agents deemed safe-in-humans as outputs. Using sequences for SARS-CoV-2 as inputs to the trained models produces tentative safe-in-human antiviral candidates for treating COVID-19.
• Score: 0.47791962198275073
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: The integration of machine learning methods into bioinformatics provides particular benefits in identifying how therapeutics effective in one context might have utility in an unknown clinical context or against a novel pathology. We aim to discover the underlying associations between viral proteins and antiviral therapeutics that are effective against them by employing neural network models. Using the National Center for Biotechnology Information virus protein database and the DrugVirus database, which provides a comprehensive report of broad-spectrum antiviral agents (BSAAs) and viruses they inhibit, we trained ANN models with virus protein sequences as inputs and antiviral agents deemed safe-in-humans as outputs. Model training excluded SARS-CoV-2 proteins and included only Phases II, III, IV and Approved level drugs. Using sequences for SARS-CoV-2 (the coronavirus that causes COVID-19) as inputs to the trained models produces outputs of tentative safe-in-human antiviral candidates for treating COVID-19. Our results suggest multiple drug candidates, some of which complement recent findings from noteworthy clinical studies. Our in-silico approach to drug repurposing has promise in identifying new drug candidates and treatments for other viruses.

Related papers

• Virus2Vec: Viral Sequence Classification Using Machine Learning [48.40285316053593]
  We propose Virus2Vec, a feature-vector representation for viral sequences that enable machine learning models to identify viral hosts. We empirically evaluate Virus2Vec on real-world spike sequences of Coronaviridae and rabies virus sequence data to predict the host. Our results demonstrate that Virus2Vec outperforms the predictive accuracies of baseline and state-of-the-art methods.
  arXiv  Detail & Related papers  (2023-04-24T08:17:16Z)
• VDDB: a comprehensive resource and machine learning platform for antiviral drug discovery [3.49680989341015]
  Virus infection is one of the major diseases that seriously threaten human health. We presented an open-access antiviral drug resource and machine learning platform (VDDB) VDDB highlights 848 clinical vaccines, 199 clinical antibodies, as well as over 710,000 small molecules targeting 39 medically important viruses including SARS-CoV-2.
  arXiv  Detail & Related papers  (2022-09-17T09:02:46Z)
• COVID-Net Biochem: An Explainability-driven Framework to Building Machine Learning Models for Predicting Survival and Kidney Injury of COVID-19 Patients from Clinical and Biochemistry Data [66.43957431843324]
  We introduce COVID-Net Biochem, a versatile and explainable framework for constructing machine learning models. We apply this framework to predict COVID-19 patient survival and the likelihood of developing Acute Kidney Injury during hospitalization.
  arXiv  Detail & Related papers  (2022-04-24T07:38:37Z)
• Accelerating Inhibitor Discovery for Multiple SARS-CoV-2 Targets with a Single, Sequence-Guided Deep Generative Framework [47.14853881703749]
  We demonstrate the broad utility of a single deep generative framework toward discovering novel drug-like inhibitor molecules. To perform target-aware design, the framework employs a target sequence-conditioned sampling of novel molecules from a generative model. The most potent spike RBD inhibitor also emerged as a rare non-covalent antiviral with broad-spectrum activity against several SARS-CoV-2 variants.
  arXiv  Detail & Related papers  (2022-04-19T17:59:46Z)
• Deep learning for drug repurposing: methods, databases, and applications [54.08583498324774]
  Repurposing existing drugs for new therapies is an attractive solution that accelerates drug development at reduced experimental costs. In this review, we introduce guidelines on how to utilize deep learning methodologies and tools for drug repurposing.
  arXiv  Detail & Related papers  (2022-02-08T09:42:08Z)
• A k-mer Based Approach for SARS-CoV-2 Variant Identification [55.78588835407174]
  We show that preserving the order of the amino acids helps the underlying classifiers to achieve better performance. We also show the importance of the different amino acids which play a key role in identifying variants and how they coincide with those reported by the USA's Centers for Disease Control and Prevention (CDC)
  arXiv  Detail & Related papers  (2021-08-07T15:08:15Z)
• DEEMD: Drug Efficacy Estimation against SARS-CoV-2 based on cell Morphology with Deep multiple instance learning [8.716655008588361]
  Drug repurposing can accelerate the identification of effective compounds for clinical use against SARS-CoV-2. DEEMD is a computational pipeline using deep neural network models within a multiple instance learning framework. DEEMD identifies known SARS-CoV-2 inhibitors, such as Remdesivir and Aloxistatin, supporting the validity of our approach.
  arXiv  Detail & Related papers  (2021-05-10T20:38:34Z)
• Drug repurposing for COVID-19 using graph neural network and harmonizing multiple evidence [9.472330151855111]
  We built a SARS-CoV-2 knowledge graph based on the interactions among virus baits, host genes, pathways, drugs, and phenotypes. We prioritized the candidate drugs using clinical trial history, and then validated them with their genetic profiles, in vitro experimental efficacy, and electronic health records.
  arXiv  Detail & Related papers  (2020-09-23T04:47:59Z)
• PaccMann$^{RL}$ on SARS-CoV-2: Designing antiviral candidates with conditional generative models [2.0750380105212116]
  With the fast development of COVID-19 into a global pandemic, scientists around the globe are desperately searching for effective antiviral therapeutic agents. We propose a deep learning framework for conditional de novo design of antiviral candidate drugs tailored against given protein targets.
  arXiv  Detail & Related papers  (2020-05-27T11:30:15Z)
• Repurpose Open Data to Discover Therapeutics for COVID-19 using Deep Learning [22.01390057543923]
  There have been more than 850,000 confirmed cases and over 48,000 deaths from the human coronavirus disease 2019 (COVID-19) pandemic. There are currently no proven effective medications against COVID-19. This study reports an integrative, network-based deep learning methodology to identify repurposable drugs for COVID-19.
  arXiv  Detail & Related papers  (2020-05-21T16:02:29Z)
• Mapping the Landscape of Artificial Intelligence Applications against COVID-19 [59.30734371401316]
  COVID-19, the disease caused by the SARS-CoV-2 virus, has been declared a pandemic by the World Health Organization. We present an overview of recent studies using Machine Learning and, more broadly, Artificial Intelligence to tackle many aspects of the COVID-19 crisis.
  arXiv  Detail & Related papers  (2020-03-25T12:30:33Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.